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Toward a Better Understanding of...
Trehalose as a mTOR Independent 
Inducer of Autophagy in a Mouse Model of 
Tuberous Sclerosis Complex
Brennan Beeler
Mentor: Michael Wong
Tuberous sclerosis complex (TSC) is a genetic condition resulting from mutation in the 
TSC1 or TSC2 genes. TSC1 and TSC2 normally form a complex which downregulates the 
mammalian target of rapamycin (mTOR) pathway, a regulator of cellular proliferation, 
but in their absence, mTOR hyperactivation occurs. This causes the development of 
benign tumors throughout multiple organ systems, leading to systemic problems, the 
most concerning of which are neurological symptoms like seizures and autism spectrum 
disorder.
A major downstream target of mTOR is autophagy, a catabolic process which breaks 
down cellular waste, and whose dysregulation may contribute to TSC pathology. As 
mTOR normally suppresses autophagy, in TSC autophagy may be excessively inhibited. 
Rapamycin (a direct mTOR inhibitor) can induce autophagy and has demonstrated 
beneficial effects in TSC mouse models, however, the mTOR pathway regulates many 
cellular processes, making side effects of rapamycin numerous. This study was designed 
to: 1) determine whether autophagy is dysregulated in a mouse model of TSC, and 2) 
test the disaccharide trehalose as a potential mTOR independent regulator of autophagy. 
Evidence has shown trehalose may have the capacity to increase autophagy levels, which 
could help reduce symptoms of TSC.
To investigate this hypothesis, Tsc1GFAP KO mice were treated with 3% trehalose, and 
autophagy activity was assessed using western blotting of autophagy pathway markers. 
These markers were compared to rapamycin treated mice, vehicle-treated wild-type, 
and KO control mice. The results demonstrated that autophagy was inhibited in KO 
mice compared to control mice, and rapamycin was effective in increasing autophagy 
levels, however, trehalose did not show a significant shift in autophagy levels relative to 
controls. Future work will assess whether this negative result with trehalose was due to a 
mechanistic compensation in the Tsc1GFAP KO mouse model, insufficient bioavailability, 
or some other factor.
